Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of SAL0120 tablets in chronic kidney disease
ChiCTR2500097378Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SAL0120 in chronic kidney disease (CKD) (4 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Urine albumin/creatinine ratio (UACR), Sitting systolic blood pressure and seated diastolic blood pressure and 1 more. Started Feb 2025; status: recruiting.
02
Drugs
SAL0120
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2500097378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097378.